$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Tucatinib Medication Guide: Detailed explanation of indications, dosage, and side effects
2026-02-01 22:25:32
Check Details
Tucatinib, a new drug to treat HER2-positive cancers
2026-02-01 22:25:32
Check Details
Tucatinib vs. pyrotinib: A comparison of drugs for the treatment of HER2-positive breast cancer
2026-02-01 22:25:32
Check Details
The effect of tucatinib in the treatment of brain metastases from HER2-positive breast cancer
2026-02-01 22:25:32
Check Details
Molotinib/mometinib: a new targeted drug for the treatment of myelofibrosis
2026-02-01 22:25:32
Check Details
How much does it cost to take molotinib/mometinib for one month?
2026-02-01 22:25:32
Check Details
Can molotinib/mometinib be purchased in China?
2026-02-01 22:25:32
Check Details
Can molotinib/mometinib be used together?
2026-02-01 22:25:32
Check Details
How effective is the treatment with molotinib/mometinib?
2026-02-01 22:25:32
Check Details
Is molotinib/mometinib on the market?
2026-02-01 22:25:32
Check Details
What are the side effects of molotinib/mometinib?
2026-02-01 22:25:32
Check Details
Who is the manufacturer of molotinib/mometinib?
2026-02-01 22:25:32
Check Details
1
2
...
1016
1017
1018
1019
1020
1021
1022
...
10238
10239
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Ganaxolone for CDKL5-Related Seizures: GABA-A Modulation, Not a Cure
2
Daraxonrasib (Rasonque): Chemical Identity and RAS Tri-Complex Mechanism
3
Vosoritide Slowing Effect: Not Always Resistance—Check Dose, Adherence, Epiphyses
4
Ramosetron ODT for IBS-D: Gender-Based Dosing and Treatment Review
5
Tamoxifen and Feeling Older: Managing Hot Flashes, Fatigue, and Skin Changes
6
Acoramidis for ATTR-CM: TTR Stabilizer to Reduce CV Death and Hospitalization
7
Vosoritide Storage and Reconstitution: Refrigerate, 90-Day Room Temp, Use Within 3 Hours
8
FDA Approves Pembrolizumab for TMB-H Solid Tumors: Threshold ≥13 mut/Mb, KEYNOTE-158 Data
9
Capmatinib for METex14 NSCLC: Test First, Monitor Toxicity
10
Vosoritide Side Effects and Pre-Injection Food/Fluid: Injection-Site Reactions, Transient Hypotension
11
Ribociclib Still Allows Recurrence: HR+/HER2- Adjuvant and Advanced Use
12
Pretomanid Mechanism and BPaL Use in Drug-Resistant TB